<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03493191</url>
  </required_header>
  <id_info>
    <org_study_id>SHR0410-101-AU</org_study_id>
    <nct_id>NCT03493191</nct_id>
  </id_info>
  <brief_title>A Single Dose Study of SHR0410 in Healthy Male Participants</brief_title>
  <official_title>A Phase I, Randomized, Double-blind, Placebo-Controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous SHR0410 in Healthy Male Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atridia Pty Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Linear Clinical Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Atridia Pty Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, single ascending-dose study to
      investigate the effect of a single intravenous (IV) dose of SHR0410 at 6 dose levels (0.5
      μg/kg, 1 μg/kg, 2 μg/kg, 5 μg/kg, 10 μg/kg and 20 μg/kg) in healthy participants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Forty eight eligible participants will be enrolled into the 6 dose cohorts. For each cohort,
      a sentinel group of 2 subjects (1 receiving SHR0410 and 1 receiving placebo) will be dosed
      first (1:1 ratio). If no drug related adverse events occur in the sentinel participants, the
      remaining 6 subjects in a cohort will be dosed on the next day or later in a 5:1 ratio (5
      subjects receiving SHR0410 and 1 subject receiving placebo). SHR0410 will be diluted in
      saline and administered as a 15 min constant dose IV infusion at a rate of 20 ml/hr on Day 1.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2018</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse events in terms of changes in Hematology</measure>
    <time_frame>Up to Day 8</time_frame>
    <description>Hemoglobin Hematocrit Erythrocytes count Mean cell volume, Mean cell hemoglobin concentration, Leukocytes count, Neutrophils count, Lymphocytes count, Monocytes count, Eosinophils count, Basophils count, Platelets count</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse events in terms of changes in Urinalysis</measure>
    <time_frame>Up to Day 8</time_frame>
    <description>Urobilinogen Dipstick urinalysis, including: pH, Specific gravity, Protein, Blood, Leukocytes, Glucose, Ketones, Bilirubin, Nitrites</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse events in terms of changes in Biochemistry (fasting)</measure>
    <time_frame>Up to Day 8</time_frame>
    <description>Including Serum creatinine, Urea, Alanine aminotransferase, Aspartate aminotransferase, Gamma glutamyl transferase, Total bilirubin, Total protein, Albumin, Alkaline phosphatase, Serum uric acid, Glucose, Triglycerides, Total cholesterol, High-density lipoprotein cholesterol, Low-density lipoprotein cholesterol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse events in terms of changes in Physical examinations</measure>
    <time_frame>Up to Day 8</time_frame>
    <description>Review of body weight and height; general appearance; head; eyes; ears/nose/throat; neck; lymph nodes; neurological and musculoskeletal systems; heart; lungs; abdomen; skin; and extremities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse events in terms of changes in Vital signs</measure>
    <time_frame>Up to Day 8</time_frame>
    <description>Oral temperature, respiratory rate, blood pressure, and pulse rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse events in terms of changes in 12-lead ECGs</measure>
    <time_frame>Up to Day 8</time_frame>
    <description>The 12-lead ECGs must be recorded after the subjects have rested in the supine position for 5 minutes to ensure a stable baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>Up to 24 hours post dose</time_frame>
    <description>Plasma SHR0410 Area Under the Concentration-time Curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the peak plasma concentration (Tmax)</measure>
    <time_frame>Up to 24 hours post dose</time_frame>
    <description>Time to Maximum Plasma SHR0410 Concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax)</measure>
    <time_frame>Up to 24 hours post dose</time_frame>
    <description>Peak Plasma SHR0410 Concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-time (T1/2)</measure>
    <time_frame>Up to 24 hours post dose</time_frame>
    <description>Half-time of SHR0410</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine output rate</measure>
    <time_frame>Up to 48 hours post dose</time_frame>
    <description>Changes in urine output rate from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum prolactin release rate</measure>
    <time_frame>Up to 48 hours post dose</time_frame>
    <description>Changes in serum prolactin release rate from baseline</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Acute Pain</condition>
  <arm_group>
    <arm_group_label>0.5 μg/kg SHR0410</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 subjects will be randomized in a 3:1 ratio to receive a single dose of either 0.5μg/kg SHR0410 (n=6) or placebo (n=2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1 μg/kg SHR0410</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 subjects will be randomized in a 3:1 ratio to receive a single dose of either 1μg/kg SHR0410 (n=6) or placebo (n=2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 μg/kg SHR0410</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 subjects will be randomized in a 3:1 ratio to receive a single dose of either 2μg/kg SHR0410 (n=6) or placebo (n=2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 μg/kg SHR0410</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 subjects will be randomized in a 3:1 ratio to receive a single dose of either 5μg/kg SHR0410 (n=6) or placebo (n=2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 μg/kg SHR0410</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 subjects will be randomized in a 3:1 ratio to receive a single dose of either 10μg/kg SHR0410 (n=6) or placebo (n=2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 μg/kg SHR0410</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 subjects will be randomized in a 3:1 ratio to receive a single dose of either 10μg/kg SHR0410 (n=6) or placebo (n=2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.5μg/kg SHR0410</intervention_name>
    <description>a single dose of 0.5μg/kg SHR0410</description>
    <arm_group_label>0.5 μg/kg SHR0410</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1μg/kg SHR0410</intervention_name>
    <description>a single dose of 2μg/kg SHR0410</description>
    <arm_group_label>1 μg/kg SHR0410</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2μg/kg SHR0410</intervention_name>
    <description>a single dose of 2μg/kg SHR0410</description>
    <arm_group_label>2 μg/kg SHR0410</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5μg/kg SHR0410</intervention_name>
    <description>a single dose of 5μg/kg SHR0410</description>
    <arm_group_label>5 μg/kg SHR0410</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10μg/kg SHR0410</intervention_name>
    <description>a single dose of 10μg/kg SHR0410</description>
    <arm_group_label>10 μg/kg SHR0410</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>20μg/kg SHR0410</intervention_name>
    <description>a single dose of 20μg/kg SHR0410</description>
    <arm_group_label>20 μg/kg SHR0410</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male between the ages of 18 and 45 years, inclusive.

          2. Body mass index (BMI) of 18.0 to 30.0 kg/m2 and a total body weight of 50 kg to 125kg,
             inclusive.

          3. Considered generally healthy upon completion of medical history, physical examination,
             vital signs, SpO2, laboratory parameters, and ECG, as judged by the Investigator.

        Exclusion Criteria:

          1. Known sensitivity to any of the components of the investigational product formulation,
             or any other opioids.

          2. Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,
             seasonal allergies at time of dosing).

          3. Any other medical or psychological condition, which in the opinion of the
             Investigator, might create undue risk to the participant or interfere with the
             participant's ability to comply with the protocol requirements, or to complete the
             study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Powell Sarah</last_name>
    <phone>+61 (0) 411 062 165</phone>
    <email>spowell@linear.org.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>Linear Clinical Research Limited</name>
      <address>
        <city>Nedlands</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Powell</last_name>
      <phone>+61 (0) 411 062 165</phone>
      <email>spowell@linear.org.au</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2018</study_first_submitted>
  <study_first_submitted_qc>April 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2018</study_first_posted>
  <last_update_submitted>May 21, 2018</last_update_submitted>
  <last_update_submitted_qc>May 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

